DBP.B: Q1 2026 delivered narrowed losses and major clinical validation for Temodex

About this update from Double Bond Pharmaceutical International Ab Class B

Q1 2026 saw improved financials with narrowed losses and a significant scientific milestone as Temodex demonstrated a 5.6-month survival benefit. Strategic focus is on licensing, portfolio control, and leveraging new clinical data for commercial growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Double Bond Pharmaceutical International Ab Class B